Use of biologics and chemotherapy in patients with inflammatory bowel diseases and cancer

RDF 

 
This item is provided by the institution :
Hellenic Gastroenterologiki Company
Repository :
Annals of Gastroenterology
see item page
in the web site of the repository *
share



Semantic enrichment/homogenization by EKT
Use of biologics and chemotherapy in patients with inflammatory bowel diseases and cancer (EN)

Jauregui-Amezaga, Aranzazu; Digestive Oncology, University Hospitals Leuven and Department of Oncology, KU Leuven, Belgium
Prenen, Hans
Vermeire, Séverine

Patients with inflammatory bowel disease have an additional risk of developing cancer compared with the general population. This is due to local chronic inflammation that leads to the development of gastrointestinal cancers and the use of thiopurines, associated with a higher risk of lymphoproliferative disorders, skin cancers, or uterine cervical cancers. Similar to the general population, a previous history of cancer in inflammatory bowel disease patients increases the risk of developing a secondary cancer. Large studies have not shown an increased risk of cancer in patients treated with biologics. In this review we discuss the prevention and treatment of cancer in patients with inflammatory bowel disease.Keywords Crohn’s disease, ulcerative colitis, anti-TNF, chemotherapy, cancerAnn Gastroenterol 2016; 29 (2): 127-136DOI: http://dx.doi.org/10.20524/aog.2016.0004 (EN)

Ελληνική Γαστροεντερολογική Εταιρία (EL)
Hellenic Gastroenterologiki Company (EN)

2016-04-01


Annals of Gastroenterology (EN)

Annals of Gastroenterology; Volume 29, No 2 (2016); 127 (EN)



*Institutions are responsible for keeping their URLs functional (digital file, item page in repository site)